Pharmaceuticals News and Research

RSS

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Ascletis today announced it received the approval from the Taiwan Food and Drug Administration (TFDA) to start phase II clinical trial for its all-oral interferon (IFN)-free regimen to treat chronic hepatitis C (CHC).

31 Aug 2015

AMRI, Saneca Pharmaceuticals collaborate to develop and market opium-derived APIs

AMRI and Saneca Pharmaceuticals, a.s. today announced a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients, ("APIs").

31 Aug 2015

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

Results of a clinical trial seem to show the first effective treatment for the negative symptoms - withdrawal, lack of emotion, and apathy - associated with schizophrenia.

31 Aug 2015

Patterson completes sale of medical business to Madison Dearborn Partners

Patterson Medical, formerly the medical business of Patterson Companies, Inc., is now an independent company with today's completion of the previously announced acquisition of Patterson Medical by Madison Dearborn Partners.

29 Aug 2015

Global 'Call to Action Summit 2015' adopts DELHI DECLARATION to end preventable maternal and child deaths

The two-day global 'Call to Action Summit 2015' concluded today with Health Ministers and heads of country delegations from 22 countries adopting the DELHI DECLARATION on 'ending preventable maternal and child deaths'. The declaration was developed as an outcome of the high-level ministerial conclave held yesterday during the summit.

29 Aug 2015

Practices for expediting corporate market research approval process for faster insights

Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. It is, therefore, absolutely critical for biopharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.

29 Aug 2015

CytomX announces filing of registration statement for proposed initial public offering of common stock

CytomX Therapeutics, Inc., a biopharmaceutical company developing Probody therapeutics for the treatment of cancer, today announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.

29 Aug 2015

Fentanyl sold as heroin causing new wave of overdose deaths

With the heroin epidemic in the United States reaching deadlier heights, Jacksonville-based Lakeview Health drug and alcohol treatment center's Dr. Philip Hemphill is helping to explain why fentanyl is causing a new wave of overdoses. Because Fentanyl is approximately 40 to 50 times more potent than pharmaceutical grade heroin and often illegally purchased unknowingly by recreational users as heroin, the risk of death skyrockets.

29 Aug 2015

Synthetic tissue environment enables spatial definition of cancer cells and macrophages

Tumors are notoriously difficult to study in their natural habitat - body tissues - but a new synthetic tissue environment may give cancer researchers the next-best look at tumor growth and behavior.

29 Aug 2015

Novel chemical virus can cross double lipid layer surrounding cells to release drugs

Viruses are able to redirect the functioning of cells in order to infect them. Inspired by their mode of action, scientists from the CNRS and Université de Strasbourg have designed a "chemical virus" that can cross the double lipid layer that surrounds cells, and then disintegrate in the intracellular medium in order to release active compounds.

29 Aug 2015

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs.

28 Aug 2015

LLS, Light The Night National Corporate Partner Teams make positive impact on patients' lives

The Leukemia & Lymphoma Society is working with thousands of national partners, sponsors and corporate teams to fund lifesaving research and support for people battling cancer through the Light The Night Walk. Together with LLS, the Light The Night National Corporate Partner Teams are raising awareness and making a positive impact on the lives of patients today, literally, by taking steps to save lives.

28 Aug 2015

Researchers successfully use alcohols as reagents in alkylation reaction

Researchers at Princeton have developed a dual catalyst system that directly installs alkyl groups--fragments containing singly bonded carbon and hydrogen atoms that have extremely useful properties for drug discovery--onto compounds called heteroarenes. The new reaction uses simple and abundant alcohols and offers a milder and more widely applicable alternative to existing strategies.

28 Aug 2015

Lack of professional guidance on The Physician Payments Sunshine Act may hinder participation in clinical trials

A research article, published today in Postgraduate Medicine, has concluded that a lack of professional guidance on how to interpret elements of The Physician Payments Sunshine Act (2010) may be having a "chilling effect" on physicians' desire to participate in clinical trials and publish results.

28 Aug 2015

New ORNL interface can identify, characterize solid or liquid sample

In mere seconds, a system developed at the Department of Energy's Oak Ridge National Laboratory can identify and characterize a solid or liquid sample, providing a valuable tool with applications in material science, forensics, pharmaceuticals, biology and chemistry.

27 Aug 2015

Breakthrough approach saves patient's eyes and life from flesh-eating disease

The National Necrotizing Fasciitis Foundation today announced that a patient's eyes—and life—were saved by doctors at Vanderbilt University Hospital in Nashville, TN, working with NNFF, NovaBay Pharmaceuticals and Dr. John Crew, director of the Advanced Wound Care Center at Seton Medical Center in Daly City, CA.

27 Aug 2015

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).

27 Aug 2015

Common gene mutation may cause brain damage associated with ALS and FTD

Johns Hopkins researchers say they have discovered some of the first steps in how a very common gene mutation causes the brain damage associated with both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

27 Aug 2015

Pharmaceuticals News and Research

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

AMRI, Saneca Pharmaceuticals collaborate to develop and market opium-derived APIs

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

Patterson completes sale of medical business to Madison Dearborn Partners

Global 'Call to Action Summit 2015' adopts DELHI DECLARATION to end preventable maternal and child deaths

Practices for expediting corporate market research approval process for faster insights

CytomX announces filing of registration statement for proposed initial public offering of common stock

Fentanyl sold as heroin causing new wave of overdose deaths

Synthetic tissue environment enables spatial definition of cancer cells and macrophages

Novel chemical virus can cross double lipid layer surrounding cells to release drugs

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

LLS, Light The Night National Corporate Partner Teams make positive impact on patients' lives

Researchers successfully use alcohols as reagents in alkylation reaction

Lack of professional guidance on The Physician Payments Sunshine Act may hinder participation in clinical trials

New ORNL interface can identify, characterize solid or liquid sample

Breakthrough approach saves patient's eyes and life from flesh-eating disease

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Common gene mutation may cause brain damage associated with ALS and FTD

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring